ecrin-mdr-crcClinical2021IPD Sharing (as of February 2022): NoUnresectable Metastatic Colorectal CancerColorectal NeoplasmsUnresectable Metastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2385614BelgiumUnited States11PembrolizumabECRIN MDRRecruitingfalseStudy of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal CancerThe purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.2021-11-152385614NCT04991948